To further validate the idea GO was reducing stemness in MCF7-derived CSCs, we used a series of well-established breast cancer stem cell markers (CD44 and CD24), and quantitatively analyzed their expression by FACS analysis. This evidence concerns the gene CD24 and breast carcinoma.